RE:RE:RE:RE:RE:RE:RE:RexallGreat that the saliva test will be picked up
https://www.accesswire.com/609838/StageZero-Life-Sciences-Launches-Saliva-PCR-Testing-for-the-Detection-of-the-SARS-CoV-2-Virus
what I liked the most - and what should be mandatory IMHO,
is the whole respiratory test panel,
allowing to see whether we have our other friendly common cold viruses around.
Should bring more operating income even for the holiday season,
since the world seems to not let go of this crazy stuff. Love it or hate it.
If they don't let go in summer, they will always extend it until end of next winter.
Rinse repeat.
+++
Again, I also like to ASK you to DD the doubled OS of the CoC protocol (aka AVRT)
in this thread:
https://stockhouse.com/companies/bullboard?symbol=t.szls&threadid=33082901
(The study was done for one cancer type, perhaps more to come.)
Point here is, the new CoC sub would really help these patients,
potentially extending their OS.
I know, not a very 'fun' thing to discuss - but essential.
Aristotle could render the biz model for the CoC in a way
to provide the AVRT almost cost free while gaining revenues with the test.
Would solve many things
- Perfect popular feedback for a nice services (AVRT)
- Using this popularity for Aristotle, early detection to avoid the worst hopefully
- Win win
Maybe this was the long winded idea for both parties to come together.
CoC alone couldn't properly being marketed yet, so here comes the mixed biz calculation.
+++
One guy also asked whether Aristotle test panel may be sold OTC as well?
I see no reason why not, they did it for single cancer tests online.
Still, the biggest chance would be via employer insurance benefits
and the newly to be acquired sub for cancer treatment (AVRT, etc .. see above).
All may depend on the price...